Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting therapy-persistent residual disease

Nature Cancer(2024)10.1038/s43018-024-00819-9Source: DataRank Database

Targeting therapy-persistent residual disease is a research paper published in Nature Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.72)OA: greenTopics (26)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Lani F. Wu ORCID,Steven J. Altschuler ORCID,Aaron N. Hata ORCID,Xiaoxiao Sun ORCID

Live enrichment

PubMed:39289594 PMC:PMC12160366 OpenAlex:https://openalex.org/W4402602280

U.S. Department of Health & Human Services | National Institutes of Health

Grant: R01 CA249291

U.S. Department of Health & Human Services | National Institutes of Health

Grant: P50 CA265826

U.S. Department of Health & Human Services | National Institutes of Health

Grant: R01 CA134832

Mark Foundation for Cancer Research

Ludwig Center at Harvard Break Through Cancer foundation

FWCI

5.72

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: https://www.springernature.com/gp/researchers/text-and-data-mining

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12160366/pdf/nihms-2084567.pdf

publisherhttps://www.nature.com/articles/s43018-024-00819-9.pdf

publisherhttps://www.nature.com/articles/s43018-024-00819-9

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12160366

Fields of Study

Chronic Lymphocytic Leukemia ResearchLung Cancer Treatments and MutationsCancer Genomics and DiagnosticsNeoplasm, ResidualHumansNeoplasmsDrug Resistance, NeoplasmAntineoplastic AgentsMolecular Targeted TherapyAnimalsNeoplasm Recurrence, Local

MeSH Terms

AnimalsAntineoplastic AgentsHumansNeoplasm Recurrence, LocalNeoplasmsNeoplasm, ResidualDrug Resistance, NeoplasmMolecular Targeted Therapy

Keywords

ResidualMinimal residual diseaseMedicineIntensive care medicineInternal medicineComputer scienceAlgorithm

Sustainable Development Goals

SDG 0: Good health and well-being

Targeting therapy-persistent residual disease

FAIR Checklist

Authors (4)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)